Gene
MRE11
MRE11 is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (12), Trial mentions (43), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MRE11. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 5 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 3 of 8,738 | 0.03% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 3 of 8,275 | 0.04% | 8 of 11,460 | 0.07% |
| 2022 | 8 of 8,285 | 0.10% | 16 of 13,598 | 0.12% |
| 2021 | 7 of 8,692 | 0.08% | 16 of 15,045 | 0.11% |
| 2020 | 6 of 7,640 | 0.08% | 6 of 14,459 | 0.04% |
| 2019 | 3 of 7,300 | 0.04% | 8 of 12,159 | 0.07% |
| 2018 | 5 of 6,927 | 0.07% | 11 of 11,854 | 0.09% |
| 2017 | 3 of 6,558 | 0.05% | 11 of 11,595 | 0.09% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| Idylla CDx MSI Test | MRE11 | Biocartis US, Inc. | Colorectal Cancer (CRC) | 2025-08-15 |
Assay-provider ledger (12)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Biocartis | Diagnostic provider | Clinical validation | 3 | September 01, 2025 |
| Agilent Technologies | Reagent supplier | Clinical validation | 1 | July 24, 2021 |
| DAKO (Carpinteria, CA, USA) - IHC antibodies and Autostainer Link 48 platform | Context dependent | Clinical validation | 1 | July 24, 2021 |
| Diatech Pharmacogenetics | Diagnostic provider | Clinical validation | 1 | July 24, 2021 |
| Qiagen (Hilden, Germany) - Mini Amp DNA extraction kit | Reagent supplier | Clinical validation | 1 | July 24, 2021 |
Showing 5 of 12 assay-provider companies.
Trial mentions (43)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03448718 | Trial eligibility (AACT) |
| NCT04508803 | Trial eligibility (AACT) |
| NCT05515575 | Trial eligibility (AACT) |
| NCT04992013 | Trial eligibility (AACT) |
| NCT04895046 | Trial eligibility (AACT) |
Showing 5 of 43 trial mentions.
Target-disease associations (84)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Ataxia-telangiectasia | disorder of visual system | Literature (Europe PMC) |
| Dystonia | phenotype | Variant curation (ClinVar / EVA) |
| Eccrine Porocarcinoma | cancer or benign tumor | Variant curation (ClinVar / EVA) |
| FRAXF syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 84 associations.
Vendor sourcing (183)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000%). Predicted Consequence/Location: Canonica... | View ClinVar record SCV005905489.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The MRE11 c.1475C>A; p.Ala492Asp variant (rs61749249) is reported in the literature in individuals with hereditary breast and ovarian cancer syndrome, colon ... | View ClinVar record SCV000604243.8 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have a histologically documented (either primary or metastatic site) diagnosis of advanced solid tumor cancer (stage IV or unresectable) o... | View trial NCT03061188 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | MRE11A | View trial NCT03061188 |
| Academic and Community Cancer Research United | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Age \>= 18 years * Histological or cytological documentation of metastatic adenocarcinoma of the biliary tract * Patients with previously identified gen... | View trial NCT04042831 |
Showing 5 of 183 sourcing records.
Trial-cited literature (127)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics | 2025 | 27 |
| Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations. | JCO precision oncology | 2025 | 9 |
| First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. | Nature medicine | 2024 | 130 |
| Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. | The Journal of clinical investigation | 2024 | 47 |
| Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults. | Nature immunology | 2024 | 33 |
Showing 5 of 127 papers.
Protein variant mentions (58)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A537P | 1 | 2015 | PMID 25741868 |
| p.C336Y | 1 | 2016 | PMID 26467025 |
| p.D142E | 1 | 2016 | PMID 26467025 |
| p.D20G | 1 | 2015 | PMID 25741868 |
| p.D41E | 1 | 2015 | PMID 25741868 |
Showing 5 of 58 variants.
Literature-extracted relations (11)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Irinotecan | Chemical | associate |
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. | 2014 |
| GEMCITABINE | Chemical | associate |
ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. | 2008 |
| Nucleosides | Chemical | associate |
ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. | 2008 |
| Prostatic Neoplasms | Disease | associate |
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. | 2021 |
| Squamous Cell Carcinoma of Head and Neck | Disease | associate |
The DNA damage response network in the treatment of head and neck squamous cell carcinoma. | 2021 |
Showing 5 of 11 relation assertions.
Organizations publishing (236)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 11 | 2008 to 2023 |
| Government of the United States of America | Government | 6 | 2014 to 2021 |
| Memorial Sloan Kettering Cancer Center | Hospital | 6 | 2012 to 2023 |
| Mayo Clinic | Hospital | 5 | 2013 to 2021 |
| Mount Sinai Health System | Hospital | 4 | 2014 to 2023 |
Showing 5 of 236 organizations.
Where MRE11 appears
- biological_process
- cancer or benign tumor
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- measurement
- nervous system disease
- phenotype
- respiratory or thoracic disease
72 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects, actionable biomarkers, and human sample screening reference.